From 6dda1bf11c5ae6e25a77e164596b1993509d0f2a Mon Sep 17 00:00:00 2001 From: Borja Robert Date: Wed, 17 Jan 2024 11:39:09 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/STOP2030___Viaje a Ghana 2023.md | 4 ++-- 1 file changed, 2 insertions(+), 2 deletions(-) diff --git a/pages/STOP2030___Viaje a Ghana 2023.md b/pages/STOP2030___Viaje a Ghana 2023.md index 831e541d..56a9df2d 100644 --- a/pages/STOP2030___Viaje a Ghana 2023.md +++ b/pages/STOP2030___Viaje a Ghana 2023.md @@ -50,8 +50,8 @@ date:: [[2023/12]] - 3 dose regimen - Continue to include – potential to inform future MDA design and improved effectiveness/cost effectiveness of MDAs, improved clinical management - Alejandro to share potential protocol/design for salivary testing of [[Albendazol]] (e.g. 48 hours after dose 3) to complement reported coverage data. - - Economics – Contributes also to WP3 (KEMRI) - - GHS RDD to consider options for inclusion of key costing data points + - Economics – Contributes also to [[STOP2030/WP3]] ([[KEMRI]]) + - [[GHS/RDD]] to consider options for inclusion of key costing data points - Discuss with GHS economist - Discuss with KEMRI (e.g. [[Stella Kepha]]) - Can be informed by ongoing work at [[London School of Hygiene & Tropical Medicine]] for the ALIVE trial (draft anticipated in [[2024/01]]) \ No newline at end of file